We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00671099
First Posted: May 5, 2008
Last Update Posted: January 22, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
University of Toyama
Chiba University
Information provided by (Responsible Party):
Yutaka Matsuoka, Japan Science and Technology Agency
  Purpose
The purpose of this study is to evaluate efficacy and safety of Polyunsaturated Fatty Acid for the prevention of Posttraumatic Stress Disorder (PTSD) in patients with accidental injuries.

Condition Intervention Phase
Trauma Posttraumatic Stress Disorder Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid Dietary Supplement: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study

Resource links provided by NLM:


Further study details as provided by Yutaka Matsuoka, Japan Science and Technology Agency:

Primary Outcome Measures:
  • Total score of Clinician-Administrated PTSD Scale [ Time Frame: Three month ]

Secondary Outcome Measures:
  • Incidence of diagnosis of PTSD (including partial PTSD) [ Time Frame: Three month, one month ]
  • Total score of Montgomery Asberg Depression Rating Scale (MADRAS) [ Time Frame: Three month, one month ]
  • Incidence of depression evaluated by Mini-International Neuropsychiatric Interview (MINI) [ Time Frame: Three month, one month ]
  • Autonomic response measured before, during and after script driven imagery and acoustic stimulation [ Time Frame: Three month ]
  • Score of Impact of Event Scale revised (IES-R) [ Time Frame: Three month, one month ]
  • Score of Hospital Anxiety and Depression scale (HADS) [ Time Frame: Three month, one month ]
  • Score of health related Quality of Life scale, SF-36 [ Time Frame: Three month, one month ]
  • Score of Conner-Davidson Resilience Scale (CD-RISC) [ Time Frame: Three month, one month ]
  • Brain-derived neurotrophic factor (BDNF) in serum [ Time Frame: Three month, one month ]
  • Number of days of leave taken from the time of injury [ Time Frame: Three month ]
  • Buss-Perry Aggression Questionnaire (BAQ) [ Time Frame: Three month, one month, baseline ]
  • Total score of Clinician-Administrated PTSD Scale (CAPS) [ Time Frame: One month ]
  • DHEA: dehydroepiandrosterone [ Time Frame: Three month, one month ]
  • NPY: neuropeptide Y [ Time Frame: Three month, one month ]
  • IL-1 beta: interleukin 1 beta [ Time Frame: Three month, one month ]
  • IL-6: interleukin 6 [ Time Frame: Three month, one month ]
  • TNF alpha: tumor necrosis factor alpha [ Time Frame: Three month, one month ]
  • D-serine [ Time Frame: Three month, one month ]
  • L-serine [ Time Frame: Three month, one month ]
  • DL-serine [ Time Frame: Three month, one month ]
  • Activin [ Time Frame: Three month, one month ]

Enrollment: 110
Study Start Date: December 2008
Study Completion Date: December 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid
Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid
A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
Placebo Comparator: 2
Placebo
Dietary Supplement: Placebo
Placebo

Detailed Description:
Accidental injuries, mostly motor vehicle accident, in civilian population are frequent events.For instance, nearly one-third of injured patients appear to develop trauma-related psychiatric illness and the major diagnoses are post-traumatic stress disorder (PTSD) and depressive disorder.Omega-3 Polyunsaturated Fatty Acid (Omega-3 PUFA) has some evidence of efficacy of treatment in patients with anxiety and mood disorders, but no evidence of preventing anxiety and mood disorders that occur subsequent to accidental injuries.We evaluate efficacy and safety of Omega-3 PUFA for the secondary prevention of Posttraumatic Stress Disorder (PTSD) and related psychiatric illness in patients with accidental injury
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18 plus years
  2. A native Japanese speaking ability
  3. Possibility to contact patients with injury in 240 hours, and dosing in oral use
  4. Physical and metal status to possible understands scope and contents in the trial and gets informed consent

Exclusion Criteria:

  1. Clearly irretrievable acute brain parenchyma damage and subdural or subarachnoidal bleeding detected by computed tomography and/or magnetic resonance imaging
  2. Cognitive impairment: Mini Mental State Examination < 24
  3. Heavy drinker or 100IU/L ≦ γGTP in administration
  4. Heavy smoker (over 40 cigarettes per day)
  5. History and current suspicion in diagnosis of psychosis and bipolar I disorder
  6. Suspicion in diagnosis of alcoholic, substance-related disorder and eating disorder
  7. Existence of marked serious symptoms such as suicidal ideation, self-harm behavior, dissociation, status of need rapidly psychiatric treatment
  8. Use of anti-epilepsy drug, lithium, ethyl icosapentate and anti-coagulant drug (for example, aspirin, warfarin, etc) within 3 month at regular intervals
  9. Use of polyunsaturated fatty acid supplement within 3 month at regular intervals
  10. Habit of eating fish over 4 times per week
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00671099


Locations
Japan
National Disaster Medical Center
Tachikawa, Tokyo, Japan, 1900014
Sponsors and Collaborators
Japan Science and Technology Agency
University of Toyama
Chiba University
Investigators
Principal Investigator: Yutaka Matsuoka, M.D.,Ph.D. National Disaster Medical Center, Tachikawa, Tokyo ,Japan
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Yutaka Matsuoka, Psychiatrist, Japan Science and Technology Agency
ClinicalTrials.gov Identifier: NCT00671099     History of Changes
Other Study ID Numbers: NDMC-TPOP-02
First Submitted: May 1, 2008
First Posted: May 5, 2008
Last Update Posted: January 22, 2014
Last Verified: January 2014

Keywords provided by Yutaka Matsuoka, Japan Science and Technology Agency:
Patients
with high-energy
admitted
intensive care unit
motor vehicle accident
falling from height
other accident

Additional relevant MeSH terms:
Disease
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Pathologic Processes
Trauma and Stressor Related Disorders
Mental Disorders